Medscape September 11, 2024
This is the first in a three-part series from Medscape Medical News on the impact of artificial intelligence (AI) on drug discovery and development. Part 2 is about the use of AI to find new applications for existing drugs. Part 3 reports on the AI’s ability to create new proteins from scratch, streamlining the creation of protein-based therapeutics.
When patients with cancer aren’t responding to treatment, doctors often sequence their tumors, hunting for biomarkers that may point to more effective therapies.
This molecular profiling is rarely done at diagnosis — it’s costly and lacks evidence to support its influence on treatment, according to Christina Curtis, MSc, PhD, director of AI and cancer genomics at the Stanford Cancer Institute.
But for...
Today's Sponsors
Today's Sponsor